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Abstract
Background: X-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of
DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of XRCC1 are suspected to have some
relationship with response to chemotherapy and overall survival of lung cancer. This meta-analysis aimed to
summarize published data on the association between the commonest SNPs of XRCC1 (Arg194Trp, C > T,
rs1799782 and Arg399Gln, G > A, rs25487) and clinical outcome of lung cancer patients.
Methods: We retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge
Infrastructure (CNKI) databases. Studies were selected using specific inclusion and exclusion criteria. Primary
outcomes included objective response (i.e., complete response + partial response vs. progressive disease + stable
disease) and overall survival (OS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were
estimated. All analyses were performed using the Stata software.
Results: Twenty-two articles were included in the present analysis. XRCC1 Arg194Trp and Arg399Gln
polymorphisms were significantly associated with response to treatment in lung cancer patients. Patients with C/T
genotype, T/T genotype and minor variant T allele at Arg194Trp were more likely to respond to platinum-based
chemotherapy compared with those with C/C genotype (C/T vs. C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs. C/C: OR,
2.06; 95%CI, 1.39-3.06; C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10). For XRCC1 Arg399Gln, G/A genotype, A/A
genotype and minor variant A allele were associated with objective response in all patients (G/A vs. G/G: OR, 0.67;
95%CI, 0.50-0.90; A/A vs. G/G: OR, 0.43; 95%CI, 0.25-0.73; A/A+G/A vs. G/G: OR, 0.63; 95%CI, 0.49-0.83). Both G/A and
A/A genotypes of XRCC1 Arg399Gln could influence overall survival of lung cancer patients (G/A vs. G/G: HR, 1.23;
95%CI, 1.06-1.44; A/A vs. G/G: HR, 2.03; 95%CI, 1.20-3.45). Interaction analysis suggested that compared with the
patients carrying C/T+T/T genotype at XRCC1 194 and G/G genotype at XRCC1 399, the patients carrying 194 C/C
and 399 G/A+A/A or 194 C/C and 399 G/G genotype showed much worse objective response.
Conclusions: Genetic polymorphisms in XRCC1 gene might be associated with overall survival and response to
platinum-based chemotherapy in lung cancer patients.
Background
Lung cancer as a major public health problem repre-
sents the most common cancer, and more than a mil-
lion people in the world die from the disease each year
[1]. Despite the recent advances, the overall five-year
survival rate of lung cancer is at only 15% in the United
States and even lower in China [2]. Platinum is one of
the most extensively used chemotherapeutic agents in
lung cancer treatment, especially for the patients in
advanced stages. However, the efficacy of platinum-
based chemotherapy varied remarkably between differ-
ent individuals, with a response rate from 26% to 60% in
lung cancer patients [3]. Genetic factors are considered
to influence the treatment effectiveness of lung cancer
[4], thus affect the prognosis of patients. There are
some molecular markers showing potential as therapeu-
tic and prognostic indicators, but none could be used
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any medium, provided the original work is properly cited.into clinical practice [5,6]. In these factors, DNA repair
capacity (DRC) is an important one. The previous study
has reported that effective host DRC may be associated
with poorer survival in patients with non-small cell lung
cancer (NSCLC) who are treated with chemotherapy [7].
It has been speculated that single nucleotide polymorph-
isms (SNPs) in DNA repair genes may change gene
expression and activity, hence influence the effectiveness
of cancer treatment and survival of patients [8]. X-ray
repair cross-complementing group 1 (XRCC1) protein
plays a central role in base excision repair (BER) path-
way by interacting with other DNA repair proteins, giv-
ing the possibility that XRCC1 has some relationship
with the response to therapy and the overall survival of
lung cancer.
The XRCC1 gene was identified by its function to
restore the DNA repair capacity in the Chinese hamster
ovary mutant cell line EM9 [9] and interact with poly
(ADP-ribose) polymerase and DNA ligase III in recog-
nizing and rejoining DNA strand breaks, as well as with
DNA polymerase b and apurinic/apyrimidinic endonu-
clease I [10-13]. The most extensively studied SNPs of
XRCC1 gene are Arg399Gln (G > A, rs25487) and
Arg194Trp (C > T, rs1799782), which have been
reported to be associated with an altered DNA repair
activity [14,15]. These polymorphisms that lead to
amino acid changes might alter the efficiency of DNA
repair and have functional significance. The functional
effect of these polymorphisms is not clear, even though
there are studies suggesting that amino acid substitu-
tions at the evolutionary conserved regions can affect
the protein ability [16]. Lamerdin et al. found that
XRCC1 gene codon 194 was at a conserved residue in
humans [17], suggesting the functional significance of
this site. Theoretically, these polymorphisms could affect
the response to cancer therapy through the removal of
DNA adducts, in hence influence the overall survival of
patients.
Some studies have reported the relationship between
polymorphisms in XRCC1 gene and clinical outcome or
overall survival of lung cancer patients [18-39], however
the results were inconsistent. So we performed a sys-
temic review and meta-analysis to assess the evidence
about effects of XRCC1 SNPs on the efficacy of che-
motherapy and overall survival in lung cancer patients.
Methods
Data sources
This meta-analysis focused on studies dealing with prog-
nostic implication of XRCC1 SNPs in patients with lung
cancer. We conducted this systematic review using a
peer-reviewed, published protocol according to the
guidelines of the Cochrane Collaboration. We retrieved
the relevant articles using the following terms “XRCC1
or X-ray repair cross complementing protein 1” and
“lung cancer or lung neoplasms” and “SNP or poly-
morphism” from PubMed, EMBASE and the China
National Knowledge Infrastructure (CNKI) databases.
Study selection and data extraction
Flow chart of the study selection process was shown in
Figure 1. Duplicate and obviously unrelated articles
were eliminated by a single reviewer (Z.C.). Abstracts of
the remaining articles were examined independently by
three reviewers (Z.C., Z.Y., and X.L.) to determine
whether the full-text article should be obtained. Articles
published in English or Chinese language, peer-reviewed
journals that assessed the relationship between germline
polymorphic variants and major outcomes of interest
were included. We selected related studies using follow-
ing inclusion criteria:
(1) Studies should contain the information to estimate
relative risks (i.e., Odds ratios [ORs], hazard ratios
[HRs]) and 95% confidence intervals (CIs) for prognostic
effect of lung cancer.
(2). The cases in studies should be advanced, recur-
rent, or metastatic lung cancer patients treated by any
of the platinum drugs.
(3) Cancer patients should be histologically or patho-
logically confirmed.
(4) SNPs in XRCC1 gene should be genotyped.
(5) The studies with cell line would be excluded.
According to these criteria, a total of 37 articles were
selected. Five studies were excluded because data that
overlapped from the same study group were published.
Three studies were excluded because critical missing
information was not obtained. As the number of rele-
vant studies was not enough, two studies with SNPs
rs25489, rs2854510 and rs1001581 in XRCC1 gene, two
studies with XRCC1 T-77C, and two studies with toxi-
city were also excluded. One study only about XRCC1
protein was also excluded. Finally we summarized the
results of 22 articles for our systematic review (Table 1).
The following information were extracted and coded
by using standard form: year of publication, country/
region of study, ethnicity, case number, cancer stage of
samples, outcomes and SNPs included in each study.
Statistical methods
We abstracted ORs, HRs and 95%CIs from all studies. If
such data were missing from some studies, we calcu-
lated the ORs and 95%CIs for objective response vs. no
response after platinum-based chemotherapy [complete
response (CR) + partial response (PR) vs. progressive
disease (PD) + stable disease (SD)] using the WHO cri-
teria or the Response Evaluation Criteria in Solid
Tumors (RECST). We then investigated the between-
study heterogeneity by the Cochran’sQt e s t( a
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Figure 1 Flow chart of the study selection process.
Table 1 Studies on prognosis and XRCC1 Arg194Trp and Arg399Gln polymorphisms included in the meta-analysis
Study Year Country Ethnicity Case No. Stage Outcome SNPs
Gao et al. [24] 2006 China Asian 57 II-IV TR XRCC1 Arg194Trp and Arg399Gln
Ding et al. [25] 2010 China Asian 54 IIIB-IV TR XRCC1 Arg399Gln
Yuan et al. [26] 2006 China Asian 200 advanced TR XRCC1 Arg194Trp
Shi et al. [27] 2006 China Asian 112 II-IV TR XRCC1 Arg194Trp and Arg399Gln
Qiu et al. [28] 2009 China Asian 107 IIIA/B-IV TR XRCC1 T-77C and Arg194Trp
Sun et al. [18] 2009 China Asian 87 IV TR XRCC1 Arg194Trp and Arg399Gln
Song et al. [19] 2007 China Asian 97 IIIB-IV TR XRCC1 Arg194Trp and Arg399Gln
Wang et al. [20] 2004 China Asian 105 IIIB-IV TR XRCC1 Arg194Trp and Arg399Gln
Hong et al. [21] 2009 China Asian 164 III-IV TR XRCC1 Arg194Trp and Arg399Gln
Jin et al. [22] 2006 China Asian 162 IIIB-IV TR XRCC1 Arg194Trp
Qian et al. [23] 2010 China Asian 107 IIIA/B-IV TR XRCC1 Arg399Gln
Cheng et al. [29] 2011 China Asian 120 advanced TR XRCC1 Arg399Gln
Giachino et al. [30] 2007 Italy Caucasian 248 IIIA/B-IV TR/OS XRCC1 Arg399Gln
Butkiewicz et al. [31] 2010 Poland Caucasian 162 I, II or IIIA OS XRCC1 Arg399Gln
de las Penas R. et al. [32] 2006 Spain Caucasian 135 IIIB-IV OS XRCC1 Arg399Gln
Yin et al. [33] 2009 China Asian 257 I- IV OS XRCC1 Arg399Gln
Sreeja et al. [34] 2008 India Caucasian 211 I- IV OS XRCC1 Arg399Gln
Gurubhagavatula et al. [35] 2004 USA Caucasian 103 IIIA/B-IV OS XRCC1 Arg399Gln
Kalikaki et al. [36] 2009 Greece Caucasian 119 IIIA/B-IV TR/OS XRCC1 Arg399Gln
Liu et al. [37] 2008 China Asian 53 I- IV OS/PFS XRCC1 Arg399Gln
Han et al. [38] 2011 Korea Asian 158 IIIB-IV OS/PFS XRCC1 Arg399Gln
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2.T o
obtain summary statistics for HRs of overall survival or
ORs of chemotherapy response, we performed initial
analyses with a fixed-effect model, and confirmatory
analyses with a random-effect model if there was signifi-
cant heterogeneity. The effect of publication bias was
examined by inverted funnel plots and the Begg’st e s t .
All of P values were two-sided and all analyses were
performed using the Stata software version 11.0 (Stata
Corp, College station, TX).
Results
The data pool was composed of 22 studies. Sample sizes
ranged from 53 to 257 (median 115.5), including 294
stage I/II and 2632 stage III/IV (total 2926) lung cancer
patients (Table 1).
XRCC1 Arg194Trp
Since the study on the association between XRCC1
Arg194Trp polymorphism with PFS or OS was too few
to be applied in the present meta-analysis, we only ana-
lyzed the association of XRCC1 Arg194Trp polymorph-
ism and objective response in lung cancer patients.
Ten studies including 1145 patients were eligible for
final analysis. The patients bearing the favorable XRCC1
194 genotypes (C/T, T/T) were more likely to respond
to platinum-based chemotherapy compared with those
with the unfavorable genotype (C/C) (C/T vs. C/C: OR,
2.54; 95% CI, 1.95-3.31; P = 0.590 for heterogeneity, I
2 =
0.0%; T/T vs. C/C: OR, 2.06; 95% CI, 1.39-3.06; P =
0.888 for heterogeneity, I
2 = 0.0%) (Figure 2). In the
dominant model, the minor variant T allele also signifi-
cantly influenced the objective response in all patients
(C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10; P =
0.830 for heterogeneity, I
2 = 0.0%). No publication bias
was detected by either the inverted funnel plot or Begg’s
test (data not shown).
XRCC1 Arg399Gln
Objective response
There were ten studies, altogether 1021 patients, quali-
fied for final analysis. As shown in Figure 3, the XRCC1
Arg399Gln polymorphism was significantly associated
with response to platinum-based chemotherapy. In the
dominant model, the G/A and A/A genotypes of
XRCC1 399 polymorphism were statistically significantly
associated with unfavorable objective response in
patients treated with platinum-based chemotherapy (G/
A vs. G/G: OR, 0.67; 95% CI, 0.50-0.90; P = 0.159 for
heterogeneity, I
2 = 32.4%; A/A vs. G/G: OR, 0.43; 95%
CI, 0.25-0.73; P = 0.965 for heterogeneity, I
2 =0 . 0 % ) .
The patients with either one or two minor variant A
allele showed poorer objective response in all patients
(G/A+A/A vs. G/G: OR, 0.63; 95% CI, 0.49-0.83; P =
0.206 for heterogeneity, I
2 = 25.8%) (Figure 3). No publi-
cation bias was indicated according to the results of the
inverted funnel plot and Begg’s test (data not shown).
Overall survival
G / Ag e n o t y p ea n dA / Ag e n o t y p eA total of eight stu-
dies (1288 patients) were included in this part of analy-
sis. Variant genotypes of XRCC1 399 polymorphism
were associated with higher risks of death for lung can-
cer patients (Figure 4). With the G/G genotype at
XRCC1 Arg399Gln being the reference, the HR for G/A
genotype was 1.23 compared to 2.03 in the A/A geno-
type (G/A vs. G/G: HR, 1.23; 95% CI, 1.06-1.44; P =
0.557 for heterogeneity, I
2 = 0.0%; A/A vs. G/G: HR,
2.03; 95% CI, 1.20-3.45; P = 0.000 for heterogeneity, I
2 =
85.9%). No publication bias was found through either
the funnel plot or Begg’s test (data not shown).
Minor variant A allele Three studies including 428
patients were eligible for analyzing the relationship
between alleles of XRCC1 399 polymorphism and overall
survival. In the dominant model, there was no evidence
for an influence of XRCC1 399 A allele on overall survi-
val of lung cancer patients (G/A and A/A vs. G/G: HR,
1.18; 95% CI, 0.93-1.50; P = 0.329 for heterogeneity, I
2 =
10.2%) (Figure 4C).
Interaction of XRCC1 Arg194Trp and Arg399Gln
polymorphisms on the objective response
Four studies including 371 patients were used to analyze
the relationship of the combinations between XRCC1
Arg194Trp and Arg399Gln genotypes with the objective
response in lung cancer patients. According to above
results in the present study and the results in available
studies analyzing the combination of SNPs, we defined
combination of XRCC1 194 C/T+T/T genotype and
XRCC1 399 G/G genotype as reference group. Combina-
tion of XRCC1 194 C/T+T/T genotype and XRCC1 399
G/A+A/A genotype were not significantly associated
with objective response (OR, 0.72; 95% CI, 0.39-1.33; P
= 0.383 for heterogeneity, I
2 = 1.8%). Combination of
XRCC1 194 C/C genotype and XRCC1 399 G/G geno-
type were significantly associated with objective
response (OR, 0.27; 95% CI, 0.14-0.53; P = 0.427 for het-
erogeneity, I
2 = 0.0%). Combination of XRCC1 194 C/C
genotype and XRCC1 399 G/A+A/A genotype were sig-
nificantly associated with objective response in all
patients (OR, 0.37; 95% CI, 0.22-0.65; P = 0.449 for het-
erogeneity, I
2 = 0.0%) (Figure 5).
Table 2 summarized the association between XRCC1
Arg194Trp and Arg399Gln polymorphisms with
response and overall survival in fixed-effect models and
random-effect models, respectively. P values for the
between-study heterogeneity were also listed in Table 2.
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There have been previous studies investigating possible
associations between XRCC1 SNPs and chemotherapy
outcomes or overall survival of lung cancer [18-39].
However these original results are inconsistent and until
now the lack of systematic review evaluation failed to
give further insights on this issue. We showed, by an
extensive quantitative and systematic review of






Figure 2 Forest plot of objective response in lung cancer patients treated with chemotherapy by XRCC1 Arg194Trp polymorphism: (A)
C/T vs.C/C; (B) T/T vs. C/C; (C) C/T+T/T vs. C/C.
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Page 5 of 12published reports, that XRCC1 194 C/T and XRCC1 399
G/A SNPs were associated with objective response and
XRCC1 399 G/A genotype and A/A genotype could
influence overall survival of lung cancer patients.
Furthermore, interaction analysis suggested that com-
pared with the patients carrying C/T+T/T genotype at
XRCC1 194 and G/G genotype at XRCC1 399, the
patients carrying 194 C/C and 399 G/A+A/A or 194 C/






Figure 3 Forest plot of objective response in lung cancer patients treated with chemotherapy by XRCC1 Arg399Gln polymorphism: (A)
G/A vs.G/G; (B) A/A vs. G/G; (C) G/A+A/A vs.G/G.
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Page 6 of 12C and 399 G/G genotype showed much worse objective
response.
Platinum agents are activated intracellularly to form
reactive platinum complexes that bind to DNA, thereby
inducing intrastrand and interstrand DNA cross-links,
as well as DNA-protein cross-links. These platinum-
induced DNA and protein effects result in apoptosis and
















































Figure 4 Forest plot of overall survival in lung cancer patients treated with chemotherapy by XRCC1 Arg399Gln polymorphism: (A) G/
A vs.G/G; (B) A/A vs. G/G; (C) G/A+A/A vs.G/G.
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Figure 5 Forest plot of objective response in lung cancer patients treated with chemotherapy by combinations of XRCC1 Arg194Trp
and XRCC1 Arg399Gln polymorphisms: (A) combination of 194 C/T+T/T and 399 G/A+A/A vs. combination of 194 C/T+T/T and 399 G/G; (B)
combination of 194 C/C and 399 G/G vs. combination of 194 C/T+T/T and 399 G/G; (C) combination of 194 C/C and 399 G/A+A/A vs.
combination of 194 C/T+T/T and 399 G/G.
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antitumor effects, among which DNA damage recogni-
tion and repair are important. Cancer cells may be able
to resist against the platinum-based chemotherapy when
its DNA repair ability is enhanced to remove those
DNA adducts caused by platinum agents. There is evi-
dence that lung cancer patients with a lower DNA
repair capacity had an increased overall survival after
the first-line platinum-based chemotherapy [7].
Genetic polymorphisms can contribute directly to the
variety in phenotypic drug sensitivity by modifying func-
tions of the related genes. SNPs as either prognostic or
predictive biomarkers have many advantages, especially
in the advanced cancer setting. Firstly, it is relatively
easy to obtain the human specimen for detecting SNP.
Secondly, the method to detect SNP is precise and prac-
tical. Finally, some biomarkers are detected by specia-
lized and mostly body-harmed methods; otherwise SNP
detecting could avoid these problems.
The XRCC1 protein is considered to play an impor-
tant role in DNA damage repair. XRCC1 Arg194Trp
and Arg399Gln polymorphisms were the commonest
one among more than 60 validated SNPs in XRCC1
gene and showed no major variations by ethnicity [40].
XRCC1 SNPs have been reported to be associated with
an altered DNA repair activity [14,15]. Previous reports
have also suggested that XRCC1 polymorphisms might
be risk factors for the development of lung cancer
[41-46] and promising predictive or prognostic makers
for lung cancer patients [33-35,47]. Therefore, functional
SNPs in XRCC1 gene may relate with platinum sensitiv-
ity and have prognostic values among lung cancer
patients. With a pooled dataset of 2926 patients, we per-
formed a comprehensive and systematic evaluation of
clinical outcomes by objective response and overall sur-
vival. We are delighted to find the statistically significant
association between XRCC1 SNPs with objective
response and overall survival of lung cancer, which were
not significant in previous original reports.
Meanwhile, the interaction between these two SNPs of
XRCC1 gene in the objective response was analyzed for
the first time. It is important to analyze multiple SNPs
and their interaction to find more reliable prognostic or
predictive biomarkers, because it is hard to predict com-
plex clinical outcomes of lung cancer patients by using
only one SNP. Although there were only four original
studies included in the present interaction analysis, the
results are valuable. The results of interaction analysis
showed that the patients carrying 194 C/C and 399 G/A
+A/A or 194 C/C and 399 G/G genotype showed worse
objective response, suggesting C allele at XRCC1 194
may be more significantly associated with poorer objec-
tive response than A allele at XRCC1 399. The interac-
tion between these two SNPs in objective response of
lung cancer patients was not found. The reason may be
the interaction between these two SNPs does not exist
at all, or false positive report probability (FPRP) is too
higher due to the small samples i z e .S of u t u r es t u d i e s
with large sample size on analyzing multiple genes may
be necessary to explain the SNPs interaction.
T h e r ea r et h r e ei m p o r t a n tq u e s t i o n ss h o u l db e
addressed in interpreting the results of meta-analysis:
(1) were all relevant studies included in the analysis?
This is an important question but difficult to assess. We
Table 2 Association between XRCC1 Arg194Trp and Arg399Gln polymorphisms with objective response and overall
survival
XRCC1 Objective response Overall survival
Arg194Trp Study Fixed effect Random effect Phet* Study Fixed effect Random effect Phet*
C/T vs. C/C 10 2.54[1.95,3.31] 2.54[1.95,3.32] 0.590
T/T vs. C/C 10 2.06[1.39,3.06] 2.06[1.38,3.08] 0.888
T/T+C/T vs. C/C 10 2.42[1.88,3.10] 2.41[1.87,3.10] 0.830
XRCC1 Objective response Overall survival
Arg399Gln Study Fixed effect Random effect Phet* Study Fixed effect Random effect Phet*
G/A vs. G/G 9 0.67[0.50,0.90] 0.67[0.46,0.97] 0.159 8 1.23[1.06,1.44] 1.23[1.06,1.44] 0.557
A/A vs. G/G 9 0.43[0.25,0.73] 0.43[0.25,0.84] 0.965 8 1.41[1.19,1.67] 2.03[1.20,3.45] 0.000
A/A+G/A vs. G/G 10 0.63[0.49,0.83] 0.63[0.46,0.86] 0.206 3 1.18[0.93,1.50] 1.18[0.92,1.51] 0.329
Interaction Objective response Overall survival
Study Fixed effect Random effect Phet* Study Fixed effect Random effect Phet*
c2 vs. c1 4 0.72[0.39,1.33] 0.73[0.39,1.38] 0.383
c3 vs. c1 4 0.27[0.14,0.53] 0.28[0.14,0.57] 0.427
c4 vs. c1 4 0.37[0.22,0.65] 0.38[0.21,0.67] 0.449
Combinations of XRCC1 Arg194Trp and XRCC1 Arg399Gln polymorphisms: c1, combination of 194 C/T + T/T and 399 G/G; c2, combination of 194 C/T + T/T and
399 G/A + A/A; c3: combination of 194 C/C and 399 G/G; c4, combination of 194 C/C and 399 G/A + A/A.
*Phet: P values for the between-study heterogeneity.
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Page 9 of 12made every effort to search and collect studies that were
sufficient to estimate impact of XRCC1 SNPs on clinical
outcomes and survival of lung cancer as of June 2011;
(2) was there heterogeneity in the study? The differences
in study population including age, gender, smoking sta-
tus, cancer histopathology type and cancer stage, in che-
motherapy schedule of patients, and in measurement of
confounding factors and others may result in study het-
erogeneity. In the present study, the between-study het-
erogeneity was analyzed by the Cochran’s Q test (P <
0.05) and quantified by I
2. Indeed, heterogeneous effects
were observed in one subset in the present study. How-
ever, we could not separate studies further to obtain
homogeneous groups because there was no information
on confounding factors. So we performed initial analyses
with a fixed-effect model and confirmatory analyses with
random-effect model, if there was significant heteroge-
neity. At last we found the results were similar between
fixed-effect model and random-effect model. On the
other hand, when the studies, which are possible source
of heterogeneity, were excluded from the analyses, there
were similar results observed, which also showed that
the heterogeneity did not appear to impact significantly
on the results of our analyses; (3) publication bias is an
important problem in meta-analysis and occurs if scien-
tific studies with negative or null results fail to get pub-
lished; this can happen due to bias in submitting,
reviewing, accepting, publishing or aggregating scientific
literature that fails to show positive results on a particu-
lar topic; and it could make scientific literature unrepre-
sentative of the actual research studies [48]. In our
results, no evidence of publication bias was found using
standard tests such as inverted funnel and the Begg’s
test. However, we should know that these methodologies
did not completely exclude biases, because there might
have been rejection or even non-submission of negative
results.
Despite our efforts in performing a comprehensive
analysis, limitations of our meta-analysis need to be sta-
ted. First, most of the included studies differed in their
study designs, such as subject selection, chemotherapeu-
tic protocol et al. The patients in some studies also had
surgery or other treatment such as radiotherapy in addi-
tion to the chemotherapy. All these confounding factors
may influence the homogeneity between studies. Strati-
fied analyses by possible confounding factors such as
smoking history, cancer histology, and treatment
method, might be able to reduce the heterogeneity as
stated above. However, few of these studies reported
SNP genotype distribution by subgroups so such ana-
lyses were impossible to implement. Second, our ana-
lyses mostly used unadjusted estimates, because not all
published studies stated adjusted estimates, or when
they stated, the estimates in different studies were
adjusted by different possible confounding factors. How-
ever, when the available adjusted estimates were used in
our analyses, the conclusions have not been significantly
changed (data not shown). Third, we did not analyze
the association between XRCC1 SNPs and progression-
free survival because there are only two studies invol-
ving progression-free survival. Fourth, the relationship
between XRCC1 SNPs and platinum-based chemother-
apy toxicities was not able to be analyzed in the present
study, because few studies provided the related results.
In conclusion, our meta-analysis suggested that
XRCC1 Arg194Trp and Arg399Gln polymorphisms may
be associated with overall survival and response to plati-
num-based chemotherapy in lung cancer patients. Lung
cancer patients with XRCC1 194 T allele or XRCC1 399
G allele may benefit from platinum-based chemother-
apy. However, to address these issues, future prospective
studies with large sample size and even randomized
clinical trials may be necessary. Besides, efforts on ana-
lyzing multiple genes to find more reliable prognostic or
predictive biomarkers and even on studying gene-envir-
onment interaction should be made, because it is hard
to predict complex clinical outcomes of lung cancer
patients by using only single gene.
Conclusions
Genetic polymorphisms in XRCC1 gene might be asso-
ciated with overall survival and response to platinum-
based chemotherapy in lung cancer patients.
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